Jupiter Life Line Hospitals Limited (JLHL) has announced the acquisition of land for its Pune South hospital, marking a significant step in its growth strategy. The Board has approved the purchase of 11,452.07 sq. m. of land for Rs 150 cr, with a deposit of Rs 50 cr already paid, resulting in an incremental cash outflow of Rs 100 cr. This strategic move eliminates long-term lease risks and strengthens the company’s asset base in a key growth location.

Q2FY27 Performance Highlights

JLHL’s Q2FY27 performance saw a notable increase in total income to Rs 456.5 cr, up 16% YoY. The EBITDA loss at the new Dombivli hospital was Rs 0.2 cr, significantly lower than the Rs 9.5 cr loss in Q1FY27. The company’s other hospitals performed in line with expectations, contributing to overall growth.

H1FY27 Financial Overview

For H1FY27, JLHL reported total income of Rs 867.5 cr, up 16% compared to H1FY26. The EBITDA margin improved to 22.9%, driven by operational efficiencies and strategic investments. Despite initial ramp-up losses at Dombivli and higher marketing costs, the company remains optimistic about its future growth trajectory.

JLHL continues to focus on expanding its hospital network and enhancing patient care services, positioning itself for sustained growth in the healthcare sector.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Jupiter Life Line Hospitals Limited

Jupiter Life Line Hospitals Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Jupiter drops 84.1% over three months and trades near its 52-week lows. The business compounds revenue at 18.9% and profits at 38.6% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. RSI stands at 27, well into oversold territory. Yet sellers still dominated on 23 of recent sessions versus 7 for buyers, so the pressure has not fully lifted. The business compounds at 18.9% revenue and 38.6% profit CAGR, with D/E of 0.00. Yet the stock drops 84.1% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Jupiter Life Line Hospitals Limited.

Lupin Limited (LUPIN) announced the appointment of Brian Savage as President, Chief Legal Officer. Brian will lead Lupin’s global Legal, Compliance, and Intellectual Property Management Group (IPMG) functions and will be based in New Jersey. Brian joins Lupin from Teva Pharmaceuticals, where he held several senior leadership roles since 2015. Most recently, he served as Teva’s Executive Vice President and Interim Global Chief Legal Officer. During his tenure, he also led Teva’s global litigation strategy and served as General Counsel for its U.S. Generics business.

Extensive Legal Expertise

Brian brings extensive experience navigating the complex legal and regulatory landscape in the global pharmaceutical industry. He holds a Juris Doctor (J.D.) from Yale Law School and a B.A., summa cum laude, from the University of Pennsylvania. Commenting on the appointment, Lupin CEO Vinita Gupta and Managing Director Nilesh Gupta said, “We are delighted to welcome Brian to our executive leadership team. His deep understanding of the pharmaceutical industry landscape, extensive legal expertise, and proven leadership will be valuable as we continue to strengthen our governance framework, navigate an evolving regulatory environment, and advance our long term growth ambitions.”

Leadership Role

In his new role, Brian will oversee all legal, compliance, and intellectual property functions across Lupin’s global operations. His appointment is expected to further enhance the company’s governance and regulatory compliance framework, ensuring alignment with global best practices and industry standards.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Lupin Limited

Lupin Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Lupin drops 19.7% over three months and trades near its 52-week lows. The PEG of 0.12 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. The business compounds revenue at 19.1% and profits at 131.5% CAGR. That is strong double-digit growth on both counts. The stock sits at 10% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. The business compounds at 19.1% revenue and 131.5% profit CAGR, with D/E of 0.32. Yet the stock drops 19.7% in three months. The business does not deteriorate — the stock does. That gap is what long-term investors look for. Check Fundamentals of Lupin Limited.

CORONA Remedies Limited (CORONA) has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its Bhayla manufacturing facility in Ahmedabad. This certification covers both Oral Solid Dosage (OSD) and Women’s Hormone production lines. This milestone further strengthens CORONA’s manufacturing credentials and reaffirms its commitment to maintaining high standards of quality, compliance, and operational excellence.

Reaffirming the Philosophy of ‘One World, One Quality’

While India will remain the company’s primary market, contributing over 96% of its revenue, the ANVISA GMP certification further strengthens CORONA’s manufacturing credentials. This marks CORONA’s third major GMP accreditation, building on its EU-GMP approvals for the Women’s Hormone and OSD facilities and its EAEU-GMP certification for the OSD facility. Brazil represents one of the largest pharmaceutical markets in Latin America, with an estimated market size of USD 44 billion, presenting opportunities for pharmaceutical manufacturers with strong quality systems and regulatory capabilities.

Commitment to Quality and Compliance

Together, these recognitions reflect the company’s continued focus on strengthening quality systems, maintaining regulatory compliance, and fostering a culture of continuous improvement across its manufacturing operations. Commenting on this achievement, Mr. Viral Sitwala, Executive Director, CORONA Remedies Limited, said: “Quality has always been central to the way we work at CORONA Remedies. Our philosophy of ‘One World, One Quality’ reflects our belief that the standards we follow must remain consistent and uncompromised. The ANVISA GMP certification for our Bhayla manufacturing facility is an important recognition of the systems, discipline, and collective efforts that go into maintaining these standards. While India remains our primary market and the focus of our business, such accreditations further strengthen our manufacturing credentials and reaffirm our commitment to quality and compliance. We will continue to strengthen our capabilities and uphold the quality standards that guide everything we do.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of CORONA Remedies Limited

CORONA Remedies Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

CORONA holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 2.07 is on the high side. However, it is acceptable for a quality compounder with a strong moat. The business compounds revenue at 16.6% and profits at 29.7% CAGR. That is strong double-digit growth on both counts. Buyers show up with 2.0x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 16.6% and profits at 29.7%, with D/E of 0.14. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.07 premium is usually justified. Check Fundamentals of CORONA Remedies Limited.